Downregulation of ribosomal protein S6 inhibits the growth of non-small cell lung cancer by inducing cell cycle arrest, rather than apoptosis

Cancer Letters

Volumn 354, Issue 2, 2014, Pages 378-389

  Chen, Bojiang ^a   Zhang, Wen ^a,b   Gao, Jun ^c   Chen, Hong ^d   Jiang, Li ^a,e   Liu, Dan ^a   Cao, Yidan ^a   Zhao, Shuang ^a   Qiu, Zhixin ^a   Zeng, Jing ^a   Zhang, Shangfu ^a   Li, Weimin ^a  

^a SICHUAN UNIVERSITY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c Sichuan Center for Disease Control and Prevention   (China)

^d Department of Cardiovascular Ultrasound and Noninvasive Cardiology   (China)

^e AFFILIATED HOSPITAL OF NORTH SICHUAN MEDICAL COLLEGE   (China)

Author keywords

Apoptosis; Cell cycle; Growth; Non small cell lung cancer (NSCLC); Ribosomal protein S6 (rpS6)

Indexed keywords

PROTEIN S6; SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

A549 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENICITY; CELL CYCLE ARREST; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; G0 PHASE ARREST; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LENTIVIRINAE; LUNG ADENOCARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; M PHASE CELL CYCLE CHECKPOINT; MAJOR CLINICAL STUDY; MALE; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECURRENCE FREE SURVIVAL; SENESCENCE; SURVIVAL RATE; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; CELL CYCLE CHECKPOINT; GENETIC TRANSFECTION; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; XENOGRAFT;

ANIMALS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE CHECKPOINTS; DOWN-REGULATION; FEMALE; GENE KNOCKDOWN TECHNIQUES; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MICE; MIDDLE AGED; PHOSPHORYLATION; RIBOSOMAL PROTEIN S6; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84907987173     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.08.045     Document Type: Article

References (47)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J. Clin 2013, 63:11-30.
2. Ruvinsky I., Meyuhas O. Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem. Sci 2006, 31:342-348.
3. Rosner M., Schipany K., Hengstschläger M. Phosphorylation of nuclear and cytoplasmic pools of ribosomal protein S6 during cell cycle progression. Amino Acids 2013, 44:1233-1240.
4. Yano T., Ferlito M., Aponte A., Kuno A., Miura T., Murphy E., et al. Pivotal role of mTORC2 and involvement of ribosomal protein S6 in cardioprotective signaling. Circ. Res 2014, 114:1268-1280.
5. Kim Y.K., Kim S., Shin Y.J., Hur Y.S., Kim W.Y., Lee M.S., et al. Ribosomal protein S6, a target of rapamycin, is involved in the regulation of rRNA genes by possible epigenetic changes in Arabidopsis. J. Biol. Chem 2014, 289:3901-3912.
6. Ruvinsky I., Sharon N., Lerer T., Cohen H., Stolovich-Rain M., Nir T., et al. Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. Genes Dev 2005, 19:2199-2211.
7. Du W., Hálová L., Kirkham S., Atkin J., Petersen J. TORC2 and the AGC kinase Gad8 regulate phosphorylation of the ribosomal protein S6 in fission yeast. Biol. Open 2012, 1:884-888.
8. Hellyer N.J., Nokleby J.J., Thicke B.M., Zhan W.Z., Sieck G.C., Mantilla C.B. Reduced ribosomal protein s6 phosphorylation after progressive resistance exercise in growing adolescent rats. J. Strength Cond. Res 2012, 26:1657-1666.
9. Chaisuparat R., Rojanawatsirivej S., Yodsanga S. Ribosomal protein S6 phosphorylation is associated with epithelial dysplasia and squamous cell carcinoma of the oral cavity. Pathol. Oncol. Res 2013, 19:189-193.
10. Kim S.H., Jang Y.H., Chau G.C., Pyo S., Um S.H. Prognostic significance and function of phosphorylated ribosomal protein S6 in esophageal squamous cell carcinoma. Mod. Pathol 2013, 26:327-335.
11. Robb V.A., Astrinidis A., Henske E.P. Frequent of ribosomal protein S6 hyperphosphorylation in lymphangioleiomyomatosis-associated angiomyolipomas. Mod. Pathol 2006, 19:839-846.
12. Amin R.M., Hiroshima K., Miyagi Y., Kokubo T., Hoshi K., Fujisawa T., et al. Role of the PI3K/Akt, mTOR, and STK11/LKB1 pathways in the tumorigenesis of sclerosing hemangioma of the lung. Pathol. Int 2008, 58:38-44.
13. Fleming S., Mayer N.J., Vlatkovic L.J., McLean J., McConachie M., Baty D. Signalling pathways in succinate dehydrogenase B-associated renal carcinoma. Histopathology 2014, 64:477-483.
14. Buck E., Eyzaguirre A., Haley J.D., Gibson N.W., Cagnoni P., Iwata K.K. Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity. Mol. Cancer Ther 2006, 5:2051-2059.
15. Fan Q.W., Cheng C., Knight Z.A., Haas-Kogan D., Stokoe D., James C.D., et al. EGFR signals to mTOR through PKC and independently of Akt in Glioma. Sci. Signal 2009, 2:ra4.
16. Akar U., Ozpolat B., Mehta K., Lopez-Berestein G., Zhang D., Ueno N.T., et al. Targeting p70S6K prevented lung metastasis in a breast cancer xenograft model. Mol. Cancer Ther 2010, 9:1180-1187.
17. Benjamin D., Colombi M., Moroni C., Hall M.N. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat. Rev. Drug Discov 2011, 10:868-880.
18. Plas D.R., Thomas G. Tubers and tumors: rapamycin therapy for benign and malignant tumors. Curr. Opin. Cell Biol 2009, 21:230-236.
19. Travis W.D., Brambilla E., Muller-Hermelink H.K., Harris C.C. Pathology & Genetics: Tumours of the Lung, Pleura, Thymus and Heart 2004, IARC Press, Lyon, France.
20. Groome P.A., Bolejack V., Crowley J.J., Kennedy C., Krasnik M., Sobin L.H., et al. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J. Thorac. Oncol 2007, 2:694-705.
21. Sobin L.H., Wittekind C.H. TNM Classification of Malignant Tumours 2002, John Wiley & Sons, Hoboken, NJ. sixth ed.
22. Badve S., Vladislav I.T., Spaulding B., Strickland A., Hernandez S., Bird-Turner L., et al. EP1: a novel rabbit monoclonal antibody for detection of oestrogen receptor α. J. Clin. Pathol 2013, 66:1051-1057.
23. Shen Z., Zeng Y., Guo J., Wu Y., Jiang X., Ding R., et al. Over-expression of the special AT rich sequence binding protein 1 (SATB1) promotes the progression of nasopharyngeal carcinoma: association with EBV LMP-1 expression. J. Transl. Med 2013, 11:217.
24. Pace E., Ferraro M., Di Vincenzo S., Cipollina C., Gerbino S., Cigna D., et al. Comparative cytoprotective effects of carbocysteine and fluticasone propionate in cigarette smoke extract-stimulated bronchial epithelial cells. Cell Stress Chaperones 2013, 18:733-743.
25. Ramgolam K., Hamel R., Rumelhard M., Marano F., Baeza-Squiban A. Autocrine effect of EGFR ligands on the pro-inflammatory response induced by PM(2.5) exposure in human bronchial epithelial cells. Arch. Toxicol 2012, 86:1537-1546.
26. Arif T., Vasilkovsky L., Refaely Y., Konson A., Shoshan-Barmatz V. Silencing VDAC1 expression by siRNA inhibits cancer cell proliferation and tumor growth in vivo. Mol. Ther. Nucleic Acids 2014, 3:e159.
27. Singh K., Sharma A., Mir M.C., Drazba J.A., Heston W.D., Magi-Galluzzi C., et al. Autophagic flux determines cell death and survival in response to Apo2L/TRAIL (dulanermin). Mol. Cancer 2014, 13:70.
28. Firoozinia M., Zareian Jahromi M., Moghadamtousi S.Z., Nikzad S., Abdul Kadir H. PIK3CA gene amplification and PI3K p110α protein expression in breast carcinoma. Int. J. Med. Sci 2014, 11:620-625.
29. Sethi G., Chatterjee S., Rajendran P., Li F., Shanmugam M.K., Wong K.F., et al. Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo. Mol. Cancer 2014, 13:66.
30. Baik S.Y., Lim Y.A., Kang S.J., Ahn S.H., Lee W.G., Kim C.H. Effects of platelet lysate preparations on the proliferation of HaCaT cells. Ann. Lab. Med 2014, 34:43-50.
31. Nojiri S., Joh T. Albumin suppresses human hepatocellular carcinoma proliferation and the cell cycle. Int. J. Mol. Sci 2014, 15:5163-5174.
32. Bartlett R., Yerbury J.J., Sluyter R. P2X7 receptor activation induces reactive oxygen species formation and cell death in murine EOC13 microglia. Mediators Inflamm 2013, 2013:271813.
33. Jiang L., Luo M., Liu D., Chen B., Zhang W., Mai L., et al. BAD overexpression inhibits cell growth and induces apoptosis via mitochondrial-dependent pathway in non-small cell lung cancer. Cancer Cell Int 2013, 13:53.
34. Ly C., Arechiga A.F., Melo J.V., Walsh C.M., Ong S.T. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Cancer Res 2003, 63:5716-5722.
35. Masuda M., Chen W.Y., Miyanaga A., Nakamura Y., Kawasaki K., Sakuma T., et al. Alternative mTOR signal activation in sorafenib-resistant hepatocellular carcinoma cells revealed by array-based pathway profiling. Mol. Cell. Proteomics 2014, 13:1429-1438.
36. Järås M., Miller P.G., Chu L.P., Puram R.V., Fink E.C., Schneider R.K., et al. Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia. J. Exp. Med 2014, 211:605-612.
37. Tien J.C., Liu Z., Liao L., Wang F., Xu Y., Wu Y.L., et al. The steroid receptor coactivator-3 is required for the development of castration-resistant prostate cancer. Cancer Res 2013, 73:3997-4008.
38. Iida M., Brand T.M., Campbell D.A., Starr M.M., Luthar N., Traynor A.M., et al. Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab. Cancer Biol. Ther 2013, 14:481-491.
39. Andersen J.B., Mazan-Mamczarz K., Zhan M., Gorospe M., Hassel B.A. Ribosomal protein mRNAs are primary targets of regulation in RNase-L-induced senescence. RNA Biol 2009, 6:305-315.
40. Zhao H., Darzynkiewicz Z. Attenuation of replication stress-induced premature cellular senescence to assess anti-aging modalities. Curr. Protoc. Cytom 2014, 69:47.
41. Zhang C.Y., Bao W., Wang L.H. Downregulation of p16ink4a inhibits cell proliferation and induces G1 cell cycle arrest in cervical cancer cells. Int. J. Mol. Med 2014, 33:1577-1585.
42. Macha M.A., Rachagani S., Pai P., Gupta S., Lydiatt W.M., Smith R.B., et al. MUC4 regulates cellular senescence in head and neck squamous cell carcinoma through p16/Rb pathway. Oncogene 2014, Apr 21; [Epub ahead of print]. 10.1038/onc.2014.102.
43. Rozeman L.B., Szuhai K., Schrage Y.M., Rosenberg C., Tanke H.J., Taminiau A.H., et al. Array-comparative genomic hybridization of central chondrosarcoma: identification of ribosomal protein S6 and cyclin-dependent kinase 4 as candidate target genes for genomic aberrations. Cancer 2006, 107:380-388.
44. Nosrati N., Kapoor N.R., Kumar V. Combinatorial action of transcription factors orchestrates cell cycle-dependent expression of the ribosomal protein genes and ribosome biogenesis. FEBS J. 2014, 281:2339-2352.
45. Rosner M., Hengstschläger M. Evidence for cell cycle-dependent, rapamycin-resistant phosphorylation of ribosomal protein S6 at S240/244. Amino Acids 2010, 39:1487-1492.
46. Wislez M., Spencer M.L., Izzo J.G., Juroske D.M., Balhara K., Cody D.D., et al. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras. Cancer Res 2005, 65:3226-3235.
47. Jeon Y.J., Kim I.K., Hong S.H., Nan H., Kim H.J., Lee H.J., et al. Ribosomal protein S6 is a selective mediator of TRAIL-apoptotic signaling. Oncogene 2008, 27:4344-4352.